Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

ESSA Pharma Inc. (EPIX)

5.25   0.14 (2.74%) 02-25 16:00
Open: 5.24 Pre. Close: 5.11
High: 5.28 Low: 4.46
Volume: 63,901 Market Cap: 115M
ESSA Pharma Inc is a pharmaceutical company. The company is in preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.282 - 5.314 5.314 - 5.345
Low: 4.395 - 4.427 4.427 - 4.458
Close: 5.192 - 5.248 5.248 - 5.301

Technical analysis

as of: 2020-02-25 4:29:12 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.82     One year: 7.96
Support: Support1: 4.99    Support2: 4.46
Resistance: Resistance1: 5.84    Resistance2: 6.82
Pivot: 5.34
Moving Average: MA(5): 5.33     MA(20): 5.42
MA(100): 5.00     MA(250): 3.59
MACD: MACD(12,26): -0.08     Signal(9): -0.07
Stochastic oscillator: %K(14,3): 58.00     %D(3): 58.47
RSI: RSI(14): 44.10
52-week: High: 6.14  Low: 1.41  Change(%): 44.6
Average Vol(K): 3-Month: 4012  10-Days: 6095

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
EPIX has closed above bottom band by 31.7%. Bollinger Bands are 43.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to EPIX's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2019-12-13
The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.

2019-12-04
The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Ardelyx Inc (NASDAQ: ARDX )(announced positive results for the Phase 3 study of tenapanor as monotherapy for treating hyperphosphatemia in patients with chronic kidney disease on dialysis) Audentes Therapeutics Inc (NASDAQ: BOLD )( announced a deal to be bought by ASTELLAS PHARMA/ADR (OTC: ALPMY )) Axsome Therapeutics Inc (NASDAQ: AXSM )(announced positive mid-stage readout for drug to treat narcolepsy) Cassava Sciences Inc (NASDAQ: SAVA ) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Inspire Medical Systems Inc (NYSE: INSP ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Recro Pharma Inc (NASDAQ: REPH ) Xenon Pharmaceuticals Inc (NASDAQ: XENE ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 3) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Evelo Biosciences Inc (NASDAQ: EVLO ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Neon Therapeutics Inc (NASDAQ: NTGN ) Orgenesis Inc (NASDAQ: ORGS ) Predictive Oncology Inc (NASDAQ: POAI ) Protagonist Therapeutics Inc (NASDAQ: PTGX )(announced results from mid-stage study of PTG-300 in transfusion-dependent beta-thalassemia) Therapix Biosciences …

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty Generic
Shares Out. (M) 20.76
Shares Float (M) 7.37
% Held by Insiders
% Held by Institutions
Shares Short (K) 92
Shares Short P. Month (K)

Stock Financials

EPS -1.240
Book Value (p.s.) 2.370
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -21.5
Return on Equity (ttm) -35.8
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.585
Qtrly Earnings Growth
Operating Cash Flow (M) -12.25
Levered Free Cash Flow (M) -5.69

Stock Valuations

P/E -4.23
P/E Growth Ratio 0.03
P/BV 2.22
P/S
P/CF -8.90

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2018-04-24
Last Split Ratio 0.05
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.